NEW YORK ( TheStreet) -- CHANGE IN RATINGS
Abercrombie & Fitch (ANF) was downgraded to hold at TheStreet Ratings.
Cubist (CBST) was upgraded at Mizuho to buy from neutral. $77 price target. Acquisitions should help drive near-term growth, Mizuho said.
C&J Energy (CJES) was downgraded at Cowen to market perform from outperform. $22.30 price target. Fracturing services market continues to suffer from chronic oversupply, Cowen said.Ellington Financial (EFC) was upgraded to hold at TheStreet Ratings. (EOG - Get Report) was upgraded at Credit Suisse to outperform from neutral. $175 price target. Estimates were also increased, given higher oil production forecasts, Credit Suisse said. Iberiabank (IBKC) was downgraded at Oppenheimer to perform from outperform. Company is seeing pressure in mortgage banking, Oppenheimer said. K12 (LRN - Get Report) was downgraded at Robert Baird to neutral from outperform. $25 price target. Company slashed its guidance, Baird said. K12 was downgraded at BMO Capital to market perform from outperform. $22 price target. Company is seeing lower enrollment growth, BMO Capital said. Masco (MAS) was upgraded at J.P. Morgan to overweight from neutral. $21 price target. Valuation is reasonable against unaggressive 2015 estimates, J.P. Morgan said. (MRK - Get Report) was initiated with a neutral rating at Credit Suisse. $49 price target. Core franchises are facing growth challenges, Credit Suisse said. Owens Corning (OC) was upgraded at J.P. Morgan to overweight from neutral. $45 price target. More constructive view on repair/remodel focused building product names, J.P. Morgan said. Pfizer (PFE - Get Report) was initiated with an outperform rating at Credit Suisse. $34 price target. Restructuring story will likely continue to evolve, Credit Suisse said. Patterson-UTI (PTEN) was downgraded at Cowen to perform from outperform. $24 price target. Pressure pumping prices will likely show no improvement, Cowen said. Viropharma (VPHM) was downgraded at Mizuho to neutral from buy. Valuation call, based on a $39 price target, Mizuho said.